Medical Cannabis
Extracts &
Flowers
Terpenia pioneers intellectual property (IP) in innovative cannabis medications through in-house research, formulation, trials, and pharmaceutical approval.
We meticulously manufacture organic cannabis extracts and flowers meeting EU standards with a global distribution network. We deliver natural, effective cannabinoid-based medications, revolutionizing patient care through personalized approaches.
vertically integrated production
organic full-spectrum Cannabis sativa L. extracts & flowers
The cornerstone of our upcoming operations will be a 3.470m² state-of-the-art greenhouse, located in northern Greece. Here, we will cultivate purely organic medical cannabis, meticulously attending to plant genetics and data analysis.
In our adjacent extraction facility, we produce full-spectrum extracts containing a diverse array of cannabinoids, as well as numerous terpenes and flavonoids. Our commitment to quality ensures a consistent active ingredient content, resulting in end products offering both flexibility and safe dosages.
Production
Cultivation & Extraction
We expect to deliver our products with an exceptional proportion of cannabinoids, terpenes, and flavonoids due to our careful and ecological cultivation practices, combined with our advanced on-site extraction process.
Research
Plant and Human Science
We aim to advance the medical and therapeutic cannabis industry through basic and genetic research and the cutting-edge application of human and plant science, following ethical, ecological and agronomic principles.
Formulations
Generating Intellectual Property
We create unique formulations tailored to address various medical conditions, while simultaneously safeguarding proprietary techniques and discoveries through intellectual property strategies.
Clinical Trials
Advancing Novel Therapies
Our studies will be conducted in partnership with the Infectious Diseases & Immunology Department as well as the Palliative Medicine and the Center for Rare Diseases of the University Hospital Bonn.
From Plant to patient
We are fully committed to a sustainable, eco-friendly production model
Our dedication extends to ecological and ethical production and business practices. We adhere strictly to traditional, GMO- and pesticide-free cultivation methods, ensuring compliance with modern quality standards and safety requirements. Environmental sustainability is our top priority within the company.
Who we are & How we work
Our team comprises of internationally acclaimed experts from the fields of medicine, molecular biomedicine and botany. Our goals include the sustainable, long-term development of treatments with a broad spectrum of applications.
research & development
Reducing Psychotropic Side Effects & Studying Entourage Compounds
The cannabinoid Tetrahydrocannabinol (THC) is one of the key components of pharmaceutical cannabis extracts. However, the psychotropic effects of high doses of THC are generally considered undesirable in medical applications.
The forefront of our research and development efforts involves developing a compound based on natural cannabinoids with greatly reduced psychotropic side effects.
In addition to cannabinoids, other secondary plant substances found in Cannabis Sativa L., such as terpenes, are currently under investigation. These substances may have therapeutic applications themselves or, more importantly, interact pharmacologically with each other to produce a so-called entourage effect. We aim to commence studying these synergistic factors in the near future.
Contact
Get In Touch
For further information about Terpenia, inquiries about our products and research methods, or for press and other collaboration requests, please get in touch with us either by using the form below or via email.
Terpenia® Phytotherapeutics P.C.
Terpenia specializes in cultivating and producing standardized medical cannabis extracts and flowers for the Greek and other European markets.
Our primary emphasis is on the development of finished pharmaceutical formulations, focusing on generating intellectual property.
Contact
Get In Touch
Alistrati – Serres
PC 620 45
[email protected]
Consulting Office Germany
Dr. Pavlos Kokordelis
Breite Str. 161-167
50667 Köln
[email protected]
All rights reserved © 2021
